Posted by Michael Wonder on 07 Jun 2018
FDA approves Genentech’s Rituxan (rituximab) for pemphigus vulgaris
7 June 2018 - Rituxan is now FDA-approved to treat four auto-immune diseases.
Genentech today announced that the U.S. FDA has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes.
Rituxan is the first biologic therapy approved by the FDA for PV and the first major advancement in the treatment of the disease in more than 60 years. The FDA previously granted priority review, breakthrough therapy designation and orphan drug designation to Rituxan for the treatment of PV.
